Cellular Biomedicine Group, Inc.
CBMG
CBMG was delisted on the 19th of February, 2021.
17 hedge funds and large institutions have $5.13M invested in Cellular Biomedicine Group, Inc. in 2017 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 6 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
12% less capital invested
Capital invested by funds: $5.84M → $5.13M (-$714K)
15% less funds holding
Funds holding: 20 → 17 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$51.3K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
+$25.6K |
| 3 |
Barclays
London,
United Kingdom
|
+$23K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$9.06K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.05K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$594K |
| 2 |
ECM
Element Capital Management
New York
|
-$225K |
| 3 |
LP
LMR Partners
London,
United Kingdom
|
-$156K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$38K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$17.2K |
CBMG Hedge Fund Activity: Q4 2017 in Review
17 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q4 2017, worth a combined $5.13M — down 12% from $5.84M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CBMG and 3 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 4 added.
The largest buyer was Dimensional Fund Advisors, adding an estimated $51.3K. The largest seller was Millennium Management, cutting an estimated $594K.
- 17 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q4 2017, down from 20 in Q3 2017.
- Funds reported $5.13M of Cellular Biomedicine Group, Inc. stock for Q4 2017, down 12% quarter-over-quarter.
- 3 funds opened new Cellular Biomedicine Group, Inc. positions in Q4 2017 and 6 closed out, a net change of -3 holders.
- The largest Cellular Biomedicine Group, Inc. buyer in Q4 2017 was Dimensional Fund Advisors, an estimated $51.3K added.
- The largest Cellular Biomedicine Group, Inc. seller in Q4 2017 was Millennium Management, an estimated $594K sold.
Based on aggregated 13F filings for Q4 2017.